Julie Swain

Personal life

Professional background

• University of California at San Diego, Assistant Professor of Surgery, 1981-1983
• Louisiana State University at Shreveport, Chief of Cardiothoracic Surgery, 1983-1986
• National Institutes of Health, NHLBI, Senior Investigator and Senior Surgeon, 1986-1990
• University of Nevada, Professor of Surgery and Chief Cardiothoracic Surgery 1990-1995
• University of Kentucky, Professor of Surgery and Chief Cardiothoracic Surgery, 1996-2000
• National Aeronautics and Space Administration, Acting Deputy Associate Administrator, 2000-2002
• US Food and Drug Administration, Special Assistant to the Director, Division of Cardiovascular Devices 2002-2013
• Icahn School of Medicine at Mount Sinai, Department of Cardiovascular Surgery, Professor and Vice Chair, Director of Research

  Honors, decorations, awards, and distinctions

Publications

• Abraham VS, Swain JA, Forgash AJ, Williams BL, Musulin MM. Ischemic preconditioning protects against paraplegia after transient aortic occlusion in the rat. The Annals of Thoracic Surgery 2000 Feb; 69.
• Zhang P, Abraham VS, Kraft KR, Rabchevsky AG, Scheff SW, Swain JA. Hyperthermic preconditioning protects against spinal cord ischemic injury. The Annals of Thoracic Surgery 2000 Nov; 70.
• Hartz RS, Swain JA, Mickleborough L. Sixty-year perspective on coronary artery bypass grafting in women. The Journal of Thoracic and Cardiovascular Surgery 2003 Sep; 126.
• Sapirstein W, Chen E, Swain J, Zuckerman B. US FDA perspective on regulatory issues affecting circulatory assist devices. Expert review of medical devices 2006 Nov; 3.
• Swain JA, Hartz RS. Assessing quality in cardiac surgery: why this is necessary in the twenty-first century. Perfusion 2000 Jun; 15.
• Swain J, Flynn E Jr, Greely W, Hallenbeck J, Liberthson R. Patent Foramen Ovale and Extravehicular Activity. Report to NASA Office of Life and Microgravity Applications 1999 November.
• Zuckerman B, Sapirstein W, Swain J. The FDA Role in the Development of Percutaneous Heart Valve Technology.. EuroIntervention Supplements 2006; 1: A75-A78.
• Zuckerman B, Sapirstein W, Swain J. FDA perspective on clinical trial design for cardiovascular devices. Ann Thorac Surg. 2006 September; 82: 773-5.
• Aguel F, Hillebrenner M, Stewart S, Swain J, Hampshire V, Zuckerman B. US Regulatory Decisions for Heart Valves Implanted with Minimally Invasive Surgery. Cardiovascular Engineering and Technology 2011; 2: 62-65.